Celgene Reports Third Quarter 2015 Operating and Financial Results

Go back to Celgene Reports Third Quarter 2015 Operating and Financial Results

Cowen Reiterates Outperform on Celgene (CELG) Following a Soft 3Q

November 5, 2015 3:40 PM EST

Cowen reiterated an Outperform rating and $150.00 price target on Celgene (NASDAQ: CELG), following the company's 3Q earnings report. Celgene reported non-GAAP EPS of $1.23, slightly beating consensus of $1.21. Revenues of $2.33B compared to consensus of $2.39B. TThe 18% growth in product sales was driven... More

Post-Q3 Selloff in Celgene (CELG) Probably Correction Following Recent Run - RBC

November 5, 2015 9:48 AM EST

RBC affirms Celgene Corp. (Nasdaq: CELG) at Outperform with a price target of $150 following Q3 results issued earlier.

Analyst Michael Yee noted that results for Celgene were relatively inline with expectations amid recently raised guiance when the company did its RCPT deal. The... More

Celgene (CELG) Tops Q3 EPS by 2c; Guides In-Line

November 5, 2015 7:34 AM EST

Celgene (NASDAQ: CELG) reported Q3 EPS of $1.23, $0.02 better than the analyst estimate of $1.21. Revenue for the quarter came in at $2.33 billion versus the consensus estimate of $2.4 billion.

"Our strong third quarter performance and acceleration of key drivers create significant momentum in our business, further... More